Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diego L Cortinovis

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Frontiers in Medicine|February 13, 2023
Editorial: Small cell lung cancer: New drugs and strategiesDiego L Cortinovis, Alessandro Morabito
Global & Regional Health Technology Assessment|January 11, 2023
Giuseppe Pompilio, Alessandro Morabito, Diego L Cortinovis, et al.
Frontiers in Medicine|December 27, 2016
Focus on Nivolumab in NSCLCDiego L Cortinovis, Stefania Canova, Marida Abbate, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancerPaolo Bidoli, Diego L Cortinovis, Ilaria Colombo, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2025
Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?Cesare Gridelli, Ilaria Attili, Chiara Bennati, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical TrialsJulien Mazieres, Achim Rittmeyer, Shirish Gadgeel, et al.
Clinical Lung Cancer|October 15, 2019
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)Rita Chiari, Biagio Ricciuti, Lorenza Landi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2024
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016Francesco Gelsomino, Luca Boni, Marcello Tiseo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum ChemotherapyNatasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung CancerLouis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Frontiers in Medicine|February 13, 2023
Editorial: Small cell lung cancer: New drugs and strategiesDiego L Cortinovis, Alessandro Morabito
Global & Regional Health Technology Assessment|January 11, 2023
Giuseppe Pompilio, Alessandro Morabito, Diego L Cortinovis, et al.
Frontiers in Medicine|December 27, 2016
Focus on Nivolumab in NSCLCDiego L Cortinovis, Stefania Canova, Marida Abbate, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancerPaolo Bidoli, Diego L Cortinovis, Ilaria Colombo, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2025
Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?Cesare Gridelli, Ilaria Attili, Chiara Bennati, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical TrialsJulien Mazieres, Achim Rittmeyer, Shirish Gadgeel, et al.
Clinical Lung Cancer|October 15, 2019
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)Rita Chiari, Biagio Ricciuti, Lorenza Landi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2024
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016Francesco Gelsomino, Luca Boni, Marcello Tiseo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum ChemotherapyNatasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung CancerLouis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Pageof 2